European Union — European Medicines Agency & Eli Lilly and Company

European Union — European Medicines Agency: The European Union — European Medicines Agency recently recommended approval of Novo Nordisk's Semaglutide pill, which could pave the way for the first oral weight-loss drug in Europe, complementing France's reimbursement initiative.

Eli Lilly and Company: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.

European Union — European Medicines Agency: The European Union — European Medicines Agency has granted designations to MiNK Therapeutics' Fabry gene therapy program.

Eli Lilly and Company: Eli Lilly and Company has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.